- Trials with a EudraCT protocol (218)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
218 result(s) found for: Prevalence rate.
Displaying page 2 of 11.
| EudraCT Number: 2013-002748-10 | Sponsor Protocol Number: AD-02-013 | Start Date*: 2013-12-12 |
| Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo | ||
| Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati... | ||
| Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-001430-40 | Sponsor Protocol Number: 012-06 | Start Date*: 2007-05-04 |
| Sponsor Name:University Hospital Department of Cardiology | ||
| Full Title: Tiral of Invasive versus Medical therapy of Early coronary artery disease in Diabetes (TIME-DM) | ||
| Medical condition: The prevalence of type II diabetes is increasing rapidly, contributing importantly to a new "epidemic" of coronary artery disease (CAD). Atherosclerosis accounts for 65-80% of all death among diabe... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001250-21 | Sponsor Protocol Number: 2020/3078 | Start Date*: 2020-04-03 |
| Sponsor Name:GUSTAVE ROUSSY | ||
| Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients | ||
| Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003588-37 | Sponsor Protocol Number: P150952J | Start Date*: 2018-05-09 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: A randomized, placebo controlled, double blind, double dummy, multicenter trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine | |||||||||||||
| Medical condition: Smokers smoking at least 10 cigarettes/day in the past year | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-001130-13 | Sponsor Protocol Number: | Start Date*: 2007-12-05 | |||||||||||
| Sponsor Name:Malmö University Hospital | |||||||||||||
| Full Title: Hepatitis C in a cohort of patients with maintenance therapy for opiate dependence - prevalence, severity and outcome of antiviral therapy | |||||||||||||
| Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-001283-37 | Sponsor Protocol Number: GE-ARNICA-2008 | Start Date*: 2007-09-24 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
| Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users) | |||||||||||||
| Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014916-37 | Sponsor Protocol Number: A3051122 | Start Date*: 2010-03-15 | |||||||||||
| Sponsor Name:PFIZER | |||||||||||||
| Full Title: "Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces a... | |||||||||||||
| Medical condition: "Dejar de Fumar" "Smoking cessation" | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-004626-10 | Sponsor Protocol Number: 10003 | Start Date*: 2006-03-16 |
| Sponsor Name:Pulmonary Department, Gentofte Hospital | ||
| Full Title: Smoking cessation by nurses with smokelesstobacco buccal tabltes, nicotine buccal tablets, nicotine patches with repeated thearapy every 6 months for 2 years | ||
| Medical condition: Smopking (nicotine addiction/Tobacco addiction) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004813-42 | Sponsor Protocol Number: CACZ885V2201C | Start Date*: 2019-09-24 | |||||||||||
| Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
| Full Title: A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) | |||||||||||||
| Medical condition: stages AJCC v.8 IB-IIIA non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) DE (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003975-23 | Sponsor Protocol Number: IGX1-ENT-XS-16-01 | Start Date*: 2020-04-20 | |||||||||||
| Sponsor Name:Asherman Therapy S.L.U. | |||||||||||||
| Full Title: Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial. | |||||||||||||
| Medical condition: Asherman's syndrome also known as intrauterine synechiae | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002897-38 | Sponsor Protocol Number: CESTOII | Start Date*: 2017-10-27 | |||||||||||
| Sponsor Name:NFL BIOSCIENCES SAS | |||||||||||||
| Full Title: Phase II Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy | |||||||||||||
| Medical condition: Tobacco addiction | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005346-58 | Sponsor Protocol Number: RIMINI | Start Date*: 2016-10-05 | |||||||||||
| Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI) | |||||||||||||
| Medical condition: Rejection rate, graft loss or poor graft function defined as eGFR<40 ml/min in patients with kidney transplantation. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004606-60 | Sponsor Protocol Number: BP42772 | Start Date*: 2021-06-22 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W... | |||||||||||||
| Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) BE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002116-14 | Sponsor Protocol Number: CCTL019G2201J | Start Date*: 2018-10-22 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive... | ||||||||||||||||||
| Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-005033-22 | Sponsor Protocol Number: UOL001362 | Start Date*: 2019-06-19 | |||||||||||
| Sponsor Name:University of Liverpool | |||||||||||||
| Full Title: In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, reduce cardiovascular risk: An open-label, randomised, serial CT pilot s... | |||||||||||||
| Medical condition: Human immunodeficiency virus (HIV) and cardiovascular disease (CVD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:The Hospital for Sick Children | |||||||||||||
| Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
| Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004297-14 | Sponsor Protocol Number: SLH2015001 | Start Date*: 2016-06-08 |
| Sponsor Name:Streeklaboratorium voor de volksgezondheid Kennemerland | ||
| Full Title: Effectiveness of fosfomycin versus nitrofurantoin in Dutch risk groups with cystitis: a pilot study (Uri-weg study) | ||
| Medical condition: Cystitis without tissue invasion (uncomplicated cytitis) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-000596-16 | Sponsor Protocol Number: EETTMK:99/2011 | Start Date*: 2012-03-19 | |||||||||||
| Sponsor Name:Lapland Hospital District/ Lapland Central Hospital | |||||||||||||
| Full Title: Smoking Cessation of Young Adults in Northern Finland | |||||||||||||
| Medical condition: Healthy daily smoking young adults aged 18-26 years | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003188-36 | Sponsor Protocol Number: WI218780 | Start Date*: 2018-03-08 | |||||||||||
| Sponsor Name:Lapland Central Hospital | |||||||||||||
| Full Title: Keski-ikäisten pitkään tupakoineiden tupakasta vieroitus sähkötupakalla | |||||||||||||
| Medical condition: Nicotine addiction | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002660-27 | Sponsor Protocol Number: CINC280I12201 | Start Date*: 2019-12-12 |
| Sponsor Name:Novartis Pharma AG | ||
| Full Title: A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally adva... | ||
| Medical condition: non-small cell lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) GR (Completed) DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.